Literature DB >> 3978024

The effect of dose form on the bioavailability of mebendazole in man.

M Dawson, T R Watson.   

Abstract

Four different dose forms of mebendazole were administered to human volunteers, and urine was collected and assayed for mebendazole and unconjugated metabolites of mebendazole. Oral administration of mebendazole as an oily suspension slightly enhances the bioavailability of the drug, however mebendazole is not absorbed following rectal administration. The major urinary metabolite of mebendazole in humans is 2-amino-5(6)[alpha-hydroxybenzyl]benzimidazole (IV), not 2-amino-5(6) benzoylbenzimidazole (II), as previously reported.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978024      PMCID: PMC1463790          DOI: 10.1111/j.1365-2125.1985.tb02617.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects.

Authors:  J P Brugmans; D C Thienpont; I van Wijngaarden; O F Vanparijs; V L Schuermans; H L Lauwers
Journal:  JAMA       Date:  1971-07-19       Impact factor: 56.272

2.  Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease.

Authors:  A D Bryceson; R Woestenborghs; M Michiels; H van den Bossche
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

3.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

4.  4-Amino-3-(3'-methoxycarbonyl-2'-thioureido)benzophenone, a prodrug of mebendazole.

Authors:  M Dawson; T R Watson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

5.  Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.

Authors:  F Witassek; B Burkhardt; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results.

Authors:  G J Münst; G Karlaganis; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

  6 in total
  10 in total

1.  Increased systemic availability of albendazole when taken with a fatty meal.

Authors:  H Lange; R Eggers; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.

Authors:  Christopher Ma; Johnson Tran; Frank Gu; Roxanna Ochoa; Catherine Li; David Sept; Karl Werbovetz; Naomi Morrissette
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

3.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

4.  Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans.

Authors:  Yogesh Sutar; Sophie R Fulton; Sagarkumar Paul; Sophie Altamirano; Susmit Mhatre; Hiwa Saeed; Pratikkumar Patel; Sudipta Mallick; Roopal Bhat; Vandana B Patravale; Harsh Chauhan; Kirsten Nielsen; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2021-09-01       Impact factor: 5.084

5.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

6.  Pharmacokinetics of albendazole in man.

Authors:  S E Marriner; D L Morris; B Dickson; J A Bogan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Is the exclusion of children under 24 months from anthelmintic treatment justifiable?

Authors:  Antonio Montresor; Rebecca J Stoltzfus; Marco Albonico; James M Tielsch; Amy L Rice; Hababu M Chwaya; Lorenzo Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Mar-Apr       Impact factor: 2.184

8.  Safety of a New Chewable Formulation of Mebendazole for Preventive Chemotherapy Interventions to Treat Young Children in Countries with Moderate-to-High Prevalence of Soil Transmitted Helminth Infections.

Authors:  Andrew J Friedman; Said M Ali; Marco Albonico
Journal:  J Trop Med       Date:  2012-12-24

9.  An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice.

Authors:  Cong-Shan Liu; Hao-Bing Zhang; Wen Lei; Chao-Wei Zhang; Bin Jiang; Qi Zheng; Jian-Hai Yin; Xiu-Min Han
Journal:  Parasit Vectors       Date:  2014-12-10       Impact factor: 3.876

10.  Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Lydie Meheus; Vidula Sukhatme; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2014-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.